GSK plc
•CIK: 1131399•Filing: Q4 2025
**GSK plc** maintains a $799M AUM across 15 concentrated positions, signaling a focused, sector-specific investment mandate. The portfolio is heavily weighted toward biotechnology and pharmaceutical assets, notably holding BLK at $310.2M, representing a significant concentration. Further key allocations include TFC-PR ($168.9M) and BNTX ($84.7M), underpinning exposure to high-growth, innovative drug development pipelines. This structure suggests a deep conviction in specialized life science catalysts.
Total AUM
$799.0M
QoQ Performance
N/A
Positions
15
Top 10 Concentration
97.9%
Latest Filing
Q4 2025
Top Holdings Allocation
WVE
CRSP
BNTX
VIR
LYEL
IDYA
WVE38.8%
CRSP21.1%
BNTX10.6%
VIR6.5%
LYEL5.8%
IDYA5.8%
CYTK2.7%
SPRO2.7%
📈 Biggest Buys
📉 Biggest Sells
No reductions this quarter
Sector Breakdown
Other100.0%